Arianna Castagna

Arianna Castagna

Auto-generated profile, based on publicly available information

Arianna Castagna

Department of General , 27178 Visceral and Transplantation Surgery, University Hospital Heidelberg , Heidelberg , Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2021 in Nanomedicine
Verified
Journal Article
Open access
ACArianna Castagna
Arianna Castagna
AZAlexandra J Zander
Alexandra J Zander
ISIaroslaw Sautkin
Iaroslaw Sautkin
Marc SchneiderMarc Schneider
Marc Schneider
RSRanjita Shegokar
Ranjita Shegokar
Marc A. ReymondMarc A. Reymond
Marc A. Reymond
Aims: To investigate the potential of curcumin-loaded polylactic-co-glycolic acid nanoparticles (CUR-PLGA-NPs), alone and with electrostatic precipitation, for improving tissue uptake during pressu... Graphical abstract

28 July 2021 in Pleura and Peritoneum
Verified
Journal Article
Open access
PDF file
ACArianna Castagna
Arianna Castagna
ISIaroslav Sautkin
Iaroslav Sautkin
FWFrank-Jürgen Weinreich
Frank-Jürgen Weinreich
HLHannah Heejung Lee
Hannah Heejung Lee
AKAlfred Königsrainer
Alfred Königsrainer
GNGiorgi Nadiradze
Giorgi Nadiradze
Objectives: Biopsy morphology (surface/depth ratio) and sample processing might affect pharmacological measurements in peritoneal tissue. Methods: This is an ex-vivo study on inverted bovine urinary bladders (IBUB). We compared cisplatin (CIS) and doxorubicin (DOX) concentration in 81 standardized transmural punch biopsies of different diameters (6 and 12 mm). Then, we assessed the effect of dabbing the peritoneal surface before analysis. After automatized tissue homogenization with ceramic beads followed by lyophilisation, DOX concentration was quantified by high-performance liquid chromatography (HPLC), CIS concentration by atomic absorption spectroscopy. Experiments were performed in triplicate; the analysis was blinded to the sample origin. Comparisons were performed using non-parametric tests. Results: Concentrations are given in mean (CI 5–95%). Results were reproducible between experiments (for CIS p=0.783, for DOX p=0.235) and between different localizations within the IBUB (for CIS p=0.032, for DOX p=0.663). Biopsy diameter had an influence on CIS tissue concentration (6 mm biopsies: 23.2 (20.3–26.1), vs. 12 mm biopsies: 8.1 (7.2–9.2) ng/mg, p<0.001) but not on DOX: (0.46, 0.29–0.62) vs. 0.43 (0.33–0.54) ng/mg respectively, p=0.248). Dabbing the peritoneal surface reduced DOX tissue concentration (dry biopsies: 0.28 (0.12–0.43) vs. wet biopsies: 0.64 (0.35–0.93) ng/mg, p=0.025) but not CIS (23.5 (19.0–28.0) vs. 22.9 (18.9–26.9) ng/mg, respectively, p=0.735). Conclusions: Measurements of drug concentration in peritoneal tissue can be influenced by the biopsy’s surface/depth ratio and after drying the biopsy’s surface . This influence can reach a factor three, depending on the drug tested . The biopsy technique and the pre-analytical sample preparation should be standardized to ensure reliable pharmacological measurements in peritoneal tissue.

11 October 2025 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
ACA. Castagna
A. Castagna
ARA. Ramouz
A. Ramouz
ITI. Trinidad-Gutiérrez
I. Trinidad-Gutiérrez
NBNiall Brindl
Niall Brindl
ABAndreas Brandl
Andreas Brandl
The management of gastric cancer (GC) with peritoneal metastasis (PM) remains a significant clinical challenge. Despite advances in molecular profiling, the underreporting of key molecular markers in patients undergoing surgical treatment for GC with PM is concerning. Signet ring cell (SRC) histology is associated with poor prognosis and chemoresistance, while Laurén diffuse subtype is linked to a higher risk for PM. Despite the established role of HER2 in GC progression, its impact on the efficacy of surgical treatment is not clearly defined. The lack of comprehensive reporting on these and recent molecular markers underscores the need for further research. Incorporating molecular diagnostic into clinical practice could improve the personalisation of treatment for GC with PM and overcoming important drug resistance issues, enhancing the effectiveness of current therapy approaches.

16 April 2026 in Pleura and Peritoneum
Verified
Journal Article
Open access
PDF file
NBNiall Brindl
Niall Brindl
ACArianna Castagna
Arianna Castagna
TWThilo Welsch
Thilo Welsch
MAMohammed Al-Saeedi
Mohammed Al-Saeedi
MSMartin Schneider
Martin Schneider
ABAndreas Brandl
Andreas Brandl
Objectives: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is an established treatment for selected patients with colorectal peritoneal metastases (CPM). The recently proposed concept of textbook oncologic outcomes (TOO) offers a composite benchmark for surgical quality, but its applicability and prognostic relevance in CPM remain largely unexplored. Methods: We conducted a retrospective single-centre analysis of all patients undergoing CRS and HIPEC for CPM between 2007 and 2025. Primary endpoint was overall survival (OS); secondary analyses assessed individual TOO components and associated factors. Results: Eighty-four patients met inclusion criteria (age 54.1 ± 12.1 years, PCI 5.8 ± 4.5). CC0 resection was achieved in 88.1 %, severe postoperative complications occurred in 34.5 %, and reoperation was required in 20.2 % of patients. Ninety-day mortality was 1.2 %. Complete TOO was achieved in 14.3 % of patients as only 31/84 were recommended adjuvant chemotherapy. Median OS was 39.2 months. Absence of reoperation (p=0.02), and negative lymph node status (p=0.04) were significantly associated with improved OS. Conclusions: TOO was achieved in <50 % of patients, mainly due to the absence of adjuvant chemotherapy. Absence of reoperation was associated with survival, suggesting its validity as quality indicator. Refinement of TOO definitions, incorporating patient-centred recovery measures, may improve their applicability.

11 December 2025 in Pleura and Peritoneum
Verified
Journal Article
Open access
PDF file
LELucia Eberl
Lucia Eberl
HWHannah L. Williams
Hannah L. Williams
ACArianna Castagna
Arianna Castagna
NBNazim Benzerdjeb
Nazim Benzerdjeb
WSWiebke Solaß
Wiebke Solaß
Objectives: The immunology of peritoneal mesothelioma (PeM) is complex, with the tumor microenvironment (TME) playing a crucial role in disease progression. PeM frequently evades immune detection by altering the TME. Methods: This pilot study analyzed archival peritoneal biopsies from three patients with epithelioid PeM treated with intraperitoneal chemotherapy. Using immunohistochemistry and digital image analysis, we evaluated immune cell populations (T cells, B cells, and macrophages) across 19 time points, encompassing 20 histology (HE) sections, 140 immunohistochemistry (IHC) sections, and 1,120 measurement areas. Seven markers quantified immune cell infiltration in the tumor and the peritumoral regions. Results: Distinct immune marker patterns in the tumor and TME were identified, suggesting immune cell movement and activity changes at early therapy stages. Key markers, such as CD4 and CD8, exhibited correlated trends between tumor and TME, indicating synchronized immune responses. Early shifts in these markers suggested migration from the tumor to the TME, while CD68 and CD163 showed variable patient-specific patterns, potentially reflecting individual immune responses. Elevated immune marker levels correlated negatively with survival, suggesting advanced disease progression in some cases. Conclusions: This study is the first to explore sequential TME changes in PeM under treatment. PeM may evade immune response by modifying the TME, varying among patients. PIPAC’s ability to enable repeated biopsies provides a valuable approach to advancing personalized PeM therapy. Further studies are needed to confirm and specify our findings.

12 May 2026 in Digestive Surgery
Verified
Journal Article
Closed access
ACArianna Castagna
Arianna Castagna
AFAphrodite Fotiadou
Aphrodite Fotiadou
ARAli Ramouz
Ali Ramouz
PGPreslava Gesheva
Preslava Gesheva
NBNiall Brindl
Niall Brindl
ABAndreas Brandl
Andreas Brandl
Malignant peritoneal mesothelioma (MPM) is a rare and aggressive tumour with poor prognosis, often diagnosed late due to nonspecific symptoms. Current standard treatment involves systemic chemotherapy and cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), but this approach is limited to selected patients. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) has emerged as a novel technique improving drug delivery and penetration in the peritoneal cavity. This narrative review evaluates the role of PIPAC in the treatment of MPM, analysing data from clinical studies on its feasibility, safety, and efficacy. Evidence suggests that PIPAC is a well-tolerated procedure, with a manageable safety profile and potential to improve survival and tumour response in patients with unresectable or recurrent disease. Limitations in current studies include small cohorts and heterogeneous patient populations, underscoring the need for further research. PIPAC represents a promising therapeutic option, offering enhanced intraperitoneal chemotherapy (IPC) delivery with minimal systemic toxicity. Future investigations should focus on optimizing treatment protocols and evaluating long-term benefits to better define PIPAC’s role in clinical practice.